New list of medicinal products mainly affecting the central nervous system with a marketing authorisation confirmed

On 17 May 2023, the Finnish Medicines Agency Fimea confirmed a new list of medicinal products mainly affecting the central nervous system that have a marketing authorisation. The list will be valid starting 1 June 2023 until further notice, and it replaces the current list.

It is possible that new medicines with a marketing authorisation enter the market, and likewise some medicines with a marketing authorisation may leave the market. Up-to-date information on medicinal products with a marketing authorisation should be checked from the FimeaWeb service when necessary.

The list of medicinal products mainly affecting the central nervous system is referred to in the Act on Electronic Prescriptions (61/2007) and the Ministry of Social Affairs and Health Decree on the prescription of medicines (1088/2010).

The classification of pregabalin as a narcotic enters into force on 1 June 2023. Due to the new classification, the restrictions concerning medicinal products mainly affecting the central nervous system will also apply to the prescription and supply of medicinal products containing pregabalin. In addition, medicinal products containing pregabalin are also now included in the list of medicinal products mainly affecting the central nervous system with a marketing authorisation.

List of medicinal products mainly affecting the central nervous system (PDF, in Finnish)